Tempus AI, Inc. - Class A (TEM) Covered Calls

Tempus AI is a healthcare technology company that uses artificial intelligence and data analytics to personalize cancer care and improve patient outcomes. The company operates a genomic testing laboratory and maintains one of the world's largest libraries of clinical and molecular data, helping physicians make data-driven treatment decisions for oncology and other therapeutic areas.

You can sell covered calls on Tempus AI, Inc. - Class A to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for TEM (prices last updated Wed 4:16 PM ET):

Tempus AI, Inc. - Class A (TEM) Stock Quote
Last Change Bid Ask Volume P/E Market Cap
56.16 +3.60 56.20 56.34 6.8M - 9.1
Covered Calls For Tempus AI, Inc. - Class A (TEM)
Expiration Strike Call Bid Net Debit Return
If Flat		 Annualized
Return If Flat
Feb 20 56 1.39 54.95 1.9% 231%
Mar 20 55 5.60 50.74 8.4% 98.9%
Subscribers get access to the full covered call chain, and more features.

Want to make money with covered calls?  Sign Up For A Free Trial

Core Business and Products

Tempus AI operates at the intersection of artificial intelligence and precision medicine, focusing primarily on oncology. The company provides genomic sequencing and molecular profiling services through its CLIA-certified laboratory, analyzing tumor samples to identify genetic mutations and biomarkers that can guide personalized treatment decisions. Tempus has built a proprietary clinical and molecular database containing billions of data points from real-world patient records, imaging, and genomic profiles.

The company's product portfolio includes genomic testing panels (DNA and RNA sequencing), algorithm-driven insights for treatment selection, and clinical trial matching services. Tempus also offers data analytics platforms that help healthcare providers, researchers, and pharmaceutical companies extract actionable insights from complex medical data. Beyond oncology, Tempus is expanding into neuropsychiatry, cardiology, and infectious disease applications.

Competitive Landscape

Tempus competes in the precision medicine and molecular diagnostics space against several established players. Illumina dominates sequencing technology infrastructure, while Exact Sciences and Guardant Health focus on liquid biopsy and cancer screening. Foundation Medicine, now owned by Roche, is a direct competitor in comprehensive genomic profiling for cancer patients.

The company also faces competition from laboratory service providers like Quest Diagnostics and LabCorp, as well as emerging AI-driven healthcare analytics firms. Tempus differentiates itself through its integrated approach combining laboratory services, proprietary data assets, and AI-powered analytics in a single platform. The company's scale of real-world data and partnerships with leading academic medical centers provide competitive advantages in algorithm training and clinical validation.

Strategic Outlook and Innovation

Tempus continues to invest heavily in expanding its data library and enhancing its AI capabilities to improve diagnostic accuracy and treatment recommendations. The company is pursuing growth through deeper penetration in oncology while simultaneously expanding into adjacent therapeutic areas. Partnerships with pharmaceutical companies for drug development and clinical trial optimization represent a significant revenue opportunity, as does international expansion beyond the United States market.

The company is also developing multimodal AI algorithms that integrate genomic, imaging, clinical, and outcomes data to create more comprehensive patient profiles. As healthcare increasingly adopts precision medicine approaches and value-based care models, Tempus is positioned to benefit from the growing demand for data-driven diagnostic and treatment solutions.